

To,
BSE Limited
P.J. Towers,
Dalal Street, Mumbai — 400001

Date: 17.11.2024

Dear Sir/ Madam,

Sub: Audited Financial Results for the Quarter and year ended 31.03.2024

Unit: Sangam Health Care Products Limited (Scrip Code: 531625)

With reference to the subject cited, please find attached the audited financial results for the quarter ended 31.03.2024.

This is for the information and records of the Exchange, please.

Thanking you.

Yours truly,

For Sangam Health Care Products Limited

A. Bala Gopal
A. Bala Gopal
Chief Executive officer



SANGAM HEALTH CARE PRODUCTS LIMITED						
205 & 206, AMARCHAND SHARMA COMPLEX, S.P. ROAD, SECUNDERABAD						
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MAR 31, 2024						
Sl No.	Particular	Quarter ended			Year ended	
		31.03.2024 [Audited]	31.12.2023 [Un-audited]	31.03.2023 [Audited]	31.03.2024 [Audited]	31.03.2023 [Audited]
1	Revenue from Operations	296.97	353.29	225.90	1,210.84	1,075.99
2	Other income	-	-	-	-	-
	Total Income	296.97	353.29	225.90	1,210.84	1,075.99
3	Expenses:					
	Material consumed	62.73	176.13	145.47	626.38	494.61
	Changes in inventories	-	-	-	-	-
	Employees benefit expenses	109.05	20.45	46.41	190.14	303.10
	Finance Cost	1.38	0.05	3.01	2.08	3.01
	Deprecation & amortization expenses	30.56	30.43	30.43	121.85	121.72
	Other expenses	107.01	65.56	54.42	250.42	290.04
	Total Expenses	310.74	292.62	279.74	1,190.86	1,212.48
4	Profit before exceptional and extraordinary items and tax (3)	-13.77	60.67	-53.85	19.98	136.49
5	Exceptional items	-	-	-	-	-
6	Profit before tax	-13.77	60.67	-53.85	19.98	136.49
7	Tax expense:					
	(1) Current tax	-	-	-	-	-
	(2) Deferred tax	-	-	-	21.86	20.10
8	Net Profit After Tax	-13.77	60.67	-53.85	41.83	116.39
9	Other Comprehensive Income					
A	Items that will not be reclassified to statement of Profit & loss:					
	ii) rereasurement benefits for the define benefit plans	-	-	-	-	-
	iii) equity instruments through other comprehensive income	-	-	-	-	-
	iii) Defered tax relating to the above items	-	-	-	-	-
B	Net fair value loss on instrument in equity instruments	-13.77	60.67	-53.85	41.83	116.39
	Total Other Comprehensive Income /loss					
10	Total Other Comprehensive Income					
11	Paid-up Equity share capital	1,486.00	1,486.07	1,486.07	1,486.07	1,486.07
12	Other Equity	-	-	-	-	-
13	Earnings per equity share:					
	(i) Basic	-0.09	0.41	-0.36	0.28	-0.78
	(ii) Diluted					

NOTES:

- The above mentioned financial results have been reviewed by the Audit Committee and approved by the board of directors at meeting held on 17-07-2024
- In accordance with the requirement of regulation 33 of the SEBI (listing obligation and disclosure requirement) regulation 2015 the statutory auditor have performed review of the above audited financials results for quarter and year ended 31 march,2024
- The figures of quarter ended 31st march are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the respective financial year.
- The Company operates in Single Business Segment therefore Segment reporting is not applicable to the Company The statement has been prepared in accordance with companies (Indian Accounting Standards) Rules, 2015 (Ind AS). Prescribed u/s133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The adoption in Ind AS 115 "Revenue from Contracts with Customers", with effect from April,2018 did not have any significant impact to the financial results of the Company.
- Previous period figures are regrouped, rearranged, where ever necessary. The Company has only one Segment.

Place: Hyderabad
Date: 17-07-2024



Sangam Health Care Products Limited
A. Balagopal
Director
DIN: 01712903

SANGAM HEALTHCARE PRODUCTS LIMITED 205 & 206, AMARCHAND SHARMA COMPLEX, S.P. ROAD, SECUNDERABAD UNAUDITED BALANCE SHEET AS AT 31st March 2024		
PARTICULARS	As at March 31, 2024 Audited	As at March 31, 2023 Audited
I ASSETS		
(1) Non-Current Assets		
a) Property, Plant & Equipments	139.49	261.33
b) intangible Assets		-
c) Capital Work in progress		-
d) financial Assets		-
investments		-
loans		-
e) Deferred Tax Asset	19.85	-
f) other Non current assets	33.59	33.59
Total	192.93	294.92
(2) Current Assets		
a) Inventories	172.79	219.90
b) Financial Assets		
Trade Receivables	26.66	62.75
Cash & Cash Equivalents	33.43	15.62
short term Loans & advances		214.29
Other Current Assets	224.94	
Total	457.82	512.57
TOTAL ASSETS	650.75	807.49
II EQUITY & LIABILITIES		
Equity		
a) Equity Share Capital	1,486.07	1,486.07
b) Other Equity		
Reserves and Surplus	-3,537.10	-3,578.92
Total	-2,051.03	-2,092.85
2. Non-Current Liabilities		
a) Financial Liabilities Borrowings	1,911.95	2,086.46
b) Deffered Tax Liabilities		2.01
c) Long Term Provisions		-
Total	1,911.95	2,088.47
3. Current Liabilities		
(a) Financials Liabilities		
i) Short term Borrowings	21.45	21.45
ii) Trade Payables	614.54	520.65
III) Other financial liabilities		269.77
b) Other Current Liabilities		-
c) Provisions	153.83	-
d) Current Tax Liabilities		-
Total	789.83	811.87
TOTAL EQUITY AND LIABILITIES	650.75	807.49

 Place : Hyderabad
 Date : July 17, 2024

For SANGAM HEALTHCARE PRODUCTS LTD



 A. Balagopal
 Chairman and Managing Director
 DIN:01712903


SANGAM HEALTH CARE PRODUCTS LIMITED
CIN:L24230TG1993PLC016731
Cash Flow Statement as on 31st March, 2024

Particulars	31-03-2024 (₹)	31.03.2023 (₹)
A. CASH FROM OPERATING ACTIVITIES		
(Loss)/Profit before tax and extraordinary items	19.98	(136.48)
Adjustment for:		
Income tax expense recognised in profit or loss	2.08	3.01
Finance costs recognised in profit or loss	-	-
Investment income recognised in profit or loss	-	-
Gain on disposal of property, plant and equipment	-	-
Gain on disposal of a subsidiary	-	-
Gain on disposal of interest in former associate	-	-
Net (gain)/loss recorded in profit or loss on financial liabilities designated as at fair value through profit or loss	-	-
Net (gain)/loss arising on financial assets mandatorily measured at fair value through profit or loss	-	-
Net loss/(gain) arising held for trading financial liabilities	-	-
Hedge ineffectiveness on cash flow hedges	-	-
Net (gain)/loss on disposal of available-for-sale financial assets	-	-
Impairment loss recognised on trade receivables	-	-
Reversal of impairment loss on trade receivables	-	-
Depreciation and amortisation of non-current assets	121.85	121.72
Impairment of non-current assets	-	-
Net foreign exchange (gain)/loss	-	-
Expense recognised in respect of equity-settled share-based payments	-	-
Expense recognised in respect of shares issued in exchange for goods/services	-	-
Amortisation of financial guarantee contracts	-	-
Operating Profit before Working Capital Changes	143.91	(11.75)
Movement for Working Capital:		
Increase in trade and other receivables	36.10	(1.65)
(Increase)/decrease in amounts due from customers under construction contracts	-	-
(Increase)/decrease in inventories	47.10	(25.66)
(Increase)/decrease in other assets	(10.65)	24.62
(Increase)/decrease in Deferred Tax	93.90	241.41
Decrease in trade and other payables	-	-
Increase/(decrease) in amounts due to customers under construction contracts	-	-
Increase/(decrease) in provisions	-	-
(Decrease)/increase in deferred revenue	(115.93)	25.04
(Decrease)/increase in other liabilities	-	-
Cash generated from operations	194.43	252.00
- Income taxes paid	-	-
Net Cash flow before extraordinary items	194.43	252.00
-Extraordinary & Prior period items	-	-
NET CASH FROM OPERATING ACTIVITIES	194.43	252.00



B. CASH FLOW FROM INVESTING ACTIVITIES:

Particulars	31-03-2024	31.03.2023
B. CASH FLOW FROM INVESTING ACTIVITIES:		
Payments to acquire financial assets		
Proceeds on sale of financial assets	-	-
Interest received		-
Royalties and other investment income received	-	-
Dividends received from associates	-	-
Other dividends received	-	-
Amounts advanced to related parties	-	-
Repayments by related parties	-	-
Payments for property, plant and equipment	-	-
Proceeds from disposal of property, plant and equipment		-
Payments for investment property	-	-
Proceeds from disposal of investment property	-	-
Payments for intangible assets	-	-
Net cash outflow on acquisition of subsidiaries	-	-
Net cash inflow on disposal of subsidiary	-	-
Net cash inflow on disposal of associate	-	-
NET CASH FROM INVESTING ACTIVITIES (A)	-	-

C. CASH FLOW FROM FINANCING ACTIVITIES

Particulars	31-03-2024	31.03.2023
CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of equity instruments of the Company	-	-
Proceeds from issue of convertible notes	-	-
Payment for share issue costs	-	-
Payment for buy-back of shares	-	-
Payment for share buy-back costs	-	-
Proceeds from issue of redeemable preference shares	-	-
Proceeds from issue of perpetual notes	-	-
Payment for debt issue costs Proceeds from borrowings		
Repayment of borrowings	(174.51)	(232.05)
Proceeds from government loans	-	-
Proceeds on disposal of partial interest in a subsidiary that does not involve loss of control	-	-
Dividends paid on redeemable cumulative preference shares	-	-
Dividends paid to owners of the Company	-	-
Interest paid	(2.08)	(3.01)
Long Term Provisions	-	-
NET CASH FROM FINANCING ACTIVITIES	(176.59)	(235.06)
NET INCREASE IN CASH & CASH EQUIVALENTS	17.84	16.93
Cash and cash equivalents at the beginning of the year	15.62	1.21
Effects of exchange rate changes on the balance of cash held in foreign currencies	-	-
Cash and cash equivalents at the end of the year	33.46	18.14
Reconciliation of cash and cash equivalents as per the cash flow Statement		
Cash and cash equivalents (Note no.7.3)	33.46	15.62
Balance as per statement of cash flows	33.46	15.62

 For and on behalf of the Board of Directors
 SANGAM HEALTH CARE PRODUCTS LIMITED



A. Balagopal
 Chairman and Managing Director
 DIN:01712903


 Place: Hyderabad
 Date : 17 July 2024



INDEPENDENT AUDITORS' REPORT

TO THE BOARD OF DIRECTORS OF Sangam Health Care Products Limited

Report on the audit of the Standalone Annual Financial Results

Opinion

We have audited the accompanying standalone annual financial results of **Sangam Health Care Products Limited** (hereinafter referred to as the "Company") for the year ended 31 March 2024 ('standalone annual financial results'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net loss and other comprehensive income and other financial information for the year ended 31st March 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our opinion on the Standalone annual financial results.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed



under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of standalone financial statements on whether the company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the



reasonableness of accounting estimates and related disclosures in the standalone annual financial results made by the Management and Board of Directors.

- Conclude on the appropriateness of the Management and Board of Directors, use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.


Other Matters

The standalone annual financial results include the results for the quarter ended 31st March 2024 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

Our opinion on the standalone annual financial results is not modified in respect of this matter.

For **M M REDDY & CO.,**
Chartered Accountants
Firm Reg No.010371S

Date: 17-07-2024
Place: Hyderabad


M. Madhusudhana Reddy
Partner
Membership No.213077
UDIN: 24213077BKBHGI3924

